![]() |
Name |
hydroxyseiridin
|
Molecular Formula | C12H20O4 | |
IUPAC Name* |
3-(1,6-dihydroxyheptyl)-4-methyl-2H-furan-5-one
|
|
SMILES |
CC1=C(C(O)CCCCC(C)O)COC1=O
|
|
InChI |
InChI=1S/C12H20O4/c1-8(13)5-3-4-6-11(14)10-7-16-12(15)9(10)2/h8,11,13-14H,3-7H2,1-2H3
|
|
InChIKey |
DCUDDTMRYXTTLF-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 228.29 | ALogp: | 1.2 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.535 |
Caco-2 Permeability: | -4.745 | MDCK Permeability: | 0.00001290 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.285 |
Human Intestinal Absorption (HIA): | 0.08 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.137 |
Blood-Brain-Barrier Penetration (BBB): | 0.687 | Plasma Protein Binding (PPB): | 84.57% |
Volume Distribution (VD): | 3.959 | Fu: | 23.41% |
CYP1A2-inhibitor: | 0.058 | CYP1A2-substrate: | 0.758 |
CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.225 |
CYP2C9-inhibitor: | 0.021 | CYP2C9-substrate: | 0.813 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.501 |
CYP3A4-inhibitor: | 0.004 | CYP3A4-substrate: | 0.155 |
Clearance (CL): | 12.858 | Half-life (T1/2): | 0.871 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.168 |
Drug-inuced Liver Injury (DILI): | 0.035 | AMES Toxicity: | 0.012 |
Rat Oral Acute Toxicity: | 0.811 | Maximum Recommended Daily Dose: | 0.284 |
Skin Sensitization: | 0.345 | Carcinogencity: | 0.886 |
Eye Corrosion: | 0.009 | Eye Irritation: | 0.198 |
Respiratory Toxicity: | 0.076 |